12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Quizartinib: Phase I started

Astellas said in its 3Q12 earnings ending Dec. 31, 2012, that it began an open-label, dose-escalation, Japanese Phase I trial to evaluate 3 doses of once-daily oral quizartinib in 28-day cycles in up to 18 relapsed or...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >